Skip to main content
Top
Published in: AIDS and Behavior 2/2017

01-02-2017 | Original Paper

Identifying Factors Associated with Low-Adherence and Subsequent HIV Seroconversions Among South African Women Enrolled in a Biomedical Intervention Trial

Authors: Handan Wand, Gita Ramjee

Published in: AIDS and Behavior | Issue 2/2017

Login to get access

Abstract

Sub-Saharan Africa has the highest number of HIV infected individuals in the world. Developing and implementing effective biomedical interventions still remains urgent. Poor adherence has been commonly identified as one of the major barriers for the success of HIV prevention trials. A better understanding of how to improve adherence remains a research priority. In this analysis, younger age (<35 years), number of children ≤2, being single/not cohabiting and having a new partner during the study follow up were all significantly associated with poor adherence and subsequent HIV seroconversions. At population level, these three factors collectively associated with 56 % of the low level adherence and 75 % of the HIV seroconversions. Results highlighted the importance of effective adherence and comprehensive contraceptive counselling of women who enrol in HIV prevention trials. Culturally and socially appropriate methods are needed to achieve and maintain optimum adherence levels in future HIV prevention research.
Literature
1.
go back to reference Report on the global AIDS epidemic 2010. Geneva: Joint United Nations Programme on HIV/AIDS; 2010. Report on the global AIDS epidemic 2010. Geneva: Joint United Nations Programme on HIV/AIDS; 2010.
2.
go back to reference 2008 national antenatal sentinel HIV and syphilis prevalence survey, South Africa. Pretoria: National Department of Health; 2009. 2008 national antenatal sentinel HIV and syphilis prevalence survey, South Africa. Pretoria: National Department of Health; 2009.
8.
go back to reference Skoler-Karpoff S, Ramjee G, Ahmed K, Altini L, Plagianos M, Friedland B, et al. Efficacy of Carraguard for prevention of HIV infection in women in South Africa: a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372:1977–87. doi:10.1016/S0140-6736(08)61842-5.CrossRefPubMed Skoler-Karpoff S, Ramjee G, Ahmed K, Altini L, Plagianos M, Friedland B, et al. Efficacy of Carraguard for prevention of HIV infection in women in South Africa: a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372:1977–87. doi:10.​1016/​S0140-6736(08)61842-5.CrossRefPubMed
9.
go back to reference Thigpen MC, Kebaabetswa PM, Paxton L, Smith DK, Rose CE, Segolodi TM, Henderson FL, Pathak SR, Soud FA, Chillag K, Mutanhaurwa R, Chirwa LI, Kasonde M, Abebe D, Buliva E, GvetadzeR, Johnson S, Sukalac T, ThomasVT, HartC, Johnson JA, Malotte CK, Hendrix CW, Brooks JT, for the TDF2 Study Group. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med. 2012. doi:10.1056/NEJMoa1110711 Thigpen MC, Kebaabetswa PM, Paxton L, Smith DK, Rose CE, Segolodi TM, Henderson FL, Pathak SR, Soud FA, Chillag K, Mutanhaurwa R, Chirwa LI, Kasonde M, Abebe D, Buliva E, GvetadzeR, Johnson S, Sukalac T, ThomasVT, HartC, Johnson JA, Malotte CK, Hendrix CW, Brooks JT, for the TDF2 Study Group. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med. 2012. doi:10.​1056/​NEJMoa1110711
12.
go back to reference Marrazzo JM, Ramjee G, Richardson BA, Gomez K, et al. Tenofovir-based preexposure prophylaxis for hiv infection among african women. New Eng J Med. 2015;372(6):509–18.CrossRefPubMedPubMedCentral Marrazzo JM, Ramjee G, Richardson BA, Gomez K, et al. Tenofovir-based preexposure prophylaxis for hiv infection among african women. New Eng J Med. 2015;372(6):509–18.CrossRefPubMedPubMedCentral
13.
go back to reference McCormack S, Ramjee G, Kamali A, et al. Pro2000 vaginal gel for prevention of hiv-1 infection (microbicides development programme 301): a phase 3, randomised, double-blind, parallel-group trial. Lancet. 2010;376(9749):1329–37.CrossRefPubMedPubMedCentral McCormack S, Ramjee G, Kamali A, et al. Pro2000 vaginal gel for prevention of hiv-1 infection (microbicides development programme 301): a phase 3, randomised, double-blind, parallel-group trial. Lancet. 2010;376(9749):1329–37.CrossRefPubMedPubMedCentral
14.
go back to reference Abdool Karim SS, Richardson BA, Ramjee G, et al. Safety and effectiveness of buffer gel and 0. 5% PRO2000 gel for the prevention of HIV infection in women. AIDS. 2011;25(7):957–66.CrossRefPubMed Abdool Karim SS, Richardson BA, Ramjee G, et al. Safety and effectiveness of buffer gel and 0. 5% PRO2000 gel for the prevention of HIV infection in women. AIDS. 2011;25(7):957–66.CrossRefPubMed
16.
go back to reference Pool R, Montgomery CM, Morar NS, et al. A mixed methods and triangulation model for increasing the accuracy of adherence and sexual behaviour data: the microbicides development programme. PLoS One. 2010;5(7):e11600.CrossRefPubMedPubMedCentral Pool R, Montgomery CM, Morar NS, et al. A mixed methods and triangulation model for increasing the accuracy of adherence and sexual behaviour data: the microbicides development programme. PLoS One. 2010;5(7):e11600.CrossRefPubMedPubMedCentral
18.
go back to reference Friedland BA, Stoner M, Chau MM, Plagianos MG et al. Baseline Predictors of High Adherence to a Coitally Dependent Microbicide Gel Based on an Objective Marker of Use: Findings from the Carraguard Phase 3 Trial. AIDS Behav 2015. doi:10.1007/s10461-015-1123-x. Friedland BA, Stoner M, Chau MM, Plagianos MG et al. Baseline Predictors of High Adherence to a Coitally Dependent Microbicide Gel Based on an Objective Marker of Use: Findings from the Carraguard Phase 3 Trial. AIDS Behav 2015. doi:10.​1007/​s10461-015-1123-x.
20.
go back to reference Hosmer DW Jr, Lemeshow S. Applied survival analysis: regression modelling of time to event data. New York: John Wiley; 1999. Hosmer DW Jr, Lemeshow S. Applied survival analysis: regression modelling of time to event data. New York: John Wiley; 1999.
21.
22.
go back to reference Abaasa A, Crook A, Gafos M, et al. Long-term consistent use of a vaginal microbicide gel among HIV-1 sero-discordant couples in a phase III clinical trial (MDP 301) in rural south-west Uganda.Trials. 2013;14:33. doi:10.1186/1745-6215-14-33 Abaasa A, Crook A, Gafos M, et al. Long-term consistent use of a vaginal microbicide gel among HIV-1 sero-discordant couples in a phase III clinical trial (MDP 301) in rural south-west Uganda.Trials. 2013;14:33. doi:10.​1186/​1745-6215-14-33
23.
go back to reference Kahle E, Hughes J, Lingappa J, John-Stewart G, Celum C, Naku-Joloba E, et al. An empiric risk scoring tool for identifying high-risk heterosexual hiv-1-serodiscordant couples for targeted hiv-1 prevention. J Acquir Immune Defic Syndr. 2013;62:339–47.CrossRefPubMedPubMedCentral Kahle E, Hughes J, Lingappa J, John-Stewart G, Celum C, Naku-Joloba E, et al. An empiric risk scoring tool for identifying high-risk heterosexual hiv-1-serodiscordant couples for targeted hiv-1 prevention. J Acquir Immune Defic Syndr. 2013;62:339–47.CrossRefPubMedPubMedCentral
25.
go back to reference Weiss HA, Wasserheit JN, Barnabas RV, Hayes RJ, Abu-Raddad LJ; Persisting with prevention: The importance of adherence for HIV prevention Emerging Themes in Epidemiology 2008, 5:8 doi:10.1186/1742-7622-5-8 Weiss HA, Wasserheit JN, Barnabas RV, Hayes RJ, Abu-Raddad LJ; Persisting with prevention: The importance of adherence for HIV prevention Emerging Themes in Epidemiology 2008, 5:8 doi:10.​1186/​1742-7622-5-8
27.
go back to reference Amico KR, Stirratt M. Adherence to preexposure prophylaxis: current, emerging, and anticipated bases of evidence clinical Infectious Diseases 2014;59(S1):S55-60 Amico KR, Stirratt M. Adherence to preexposure prophylaxis: current, emerging, and anticipated bases of evidence clinical Infectious Diseases 2014;59(S1):S55-60
28.
go back to reference Baeten JM, Palanee-Phillips T, Brown ER, Schwartz K, Soto-Torres LE, Govender V, et al. Use of a vaginal ring containing dapivirine for HIV-1 prevention in women. N Engl J Med. 2016. doi:10.1056/NEJMoa1506110.PubMed Baeten JM, Palanee-Phillips T, Brown ER, Schwartz K, Soto-Torres LE, Govender V, et al. Use of a vaginal ring containing dapivirine for HIV-1 prevention in women. N Engl J Med. 2016. doi:10.​1056/​NEJMoa1506110.PubMed
29.
go back to reference Wallace A, Thorn M, Maguire RA, Sudol KM, Phillips DM. Assay for establishing whether microbicide applicators have been exposed to the vagina. Sex Transm Dis. 2004;31(8):465–8.CrossRefPubMed Wallace A, Thorn M, Maguire RA, Sudol KM, Phillips DM. Assay for establishing whether microbicide applicators have been exposed to the vagina. Sex Transm Dis. 2004;31(8):465–8.CrossRefPubMed
30.
go back to reference Wallace AR, Teitelbaum A, Wan L, et al. Determining the feasibility of utilizing the microbicide applicator compliance assay for use in clinical trials. Contraception. 2007;76(1):53–61.CrossRefPubMed Wallace AR, Teitelbaum A, Wan L, et al. Determining the feasibility of utilizing the microbicide applicator compliance assay for use in clinical trials. Contraception. 2007;76(1):53–61.CrossRefPubMed
Metadata
Title
Identifying Factors Associated with Low-Adherence and Subsequent HIV Seroconversions Among South African Women Enrolled in a Biomedical Intervention Trial
Authors
Handan Wand
Gita Ramjee
Publication date
01-02-2017
Publisher
Springer US
Published in
AIDS and Behavior / Issue 2/2017
Print ISSN: 1090-7165
Electronic ISSN: 1573-3254
DOI
https://doi.org/10.1007/s10461-016-1471-1

Other articles of this Issue 2/2017

AIDS and Behavior 2/2017 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.